Effects of budesonide administration combined with pulmonary surfactant on pulmonary function and safety in children with respiratory distress syndrome

Jun Wang ,Fuying Cui ,Jianmin Wang ,Manman Xu

doi:10.3760/cma.j.issn.1673-436x.2019.15.009

Abstract

Objective To investigate the effect of different doses of budesonide combined with pulmonary surfactant (PS) on pulmonary function improvement and bronchopulmonary dysplasia (BPD) in children with neonatal respiratory distress syndrome (NRDS). Methods 132 cases of premature NRDS admitted to the Second People′s Hospital of Heze City from March 2014 to July 2017 were selected.According to the random number table, they were divided into three groups (A, B and C), 44 cases in each.Group A received PS+ budesonide continuous injection of aerosol, group B was given PS+ budesonide liquid tracheal instillation, group C was given a single injection PS+ budesonide aerosol; Comparison of three groups of patients after treatment of blood gas analysis indicators, assisted ventilation duration, repeated use of PS cases, invasive ventilation cases.Three groups of children with BPD and the incidence of major complications were recorded. Results (1)The results of blood gas analysis at each time point after treatment were better than those before treatment, and partial pressure oxygen (PaO2), PaO2/fraction of inspiration O2 (FiO2) gradually increased and PaCO2, oxygen index (OI) decreased gradually with the prolongation of time, the difference was statistically significant (P 0.05). (3)There showed no significant difference in the incidence of BPD between the three groups (P>0.05). However, the incidence of moderate and severe BPD in group A was lower than that in group B and C (P 0.05). Conclusions Continuous injection of budesonide aerosol combined with PS can significantly improve pulmonary function in children, reduce the auxiliary ventilation time and the rate of repeated use of PS, and reduce the severity of BPD, which deserves clinical reference. Key words: Budesonide; Pulmonary surfactant-associated protein; Respiratory distress syndrome, newborn; Bronchopulmonary dysplasia

Full Text